Android Apple

Neuren Pharmaceuticals Limited's (ASX:NEU) Intrinsic Value Is Potentially 60% Above Its Share Price

By Yahoo! Finance   |   2 weeks ago
Neuren Pharmaceuticals Limited's (ASX:NEU) Intrinsic Value Is Potentially 60% Above Its Share Price

The analyst price target for NEU is 28% higher than the estimated fair value. By using the Discounted Cash Flow model, the intrinsic value of Neuren Pharmaceuticals Limited is evaluated based on future cash flows discounted to present value. Various valuation techniques exist, each with pros and cons.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.